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MAC and 12 had no conditioning. 31 patients engrafted after
the 2nd HSCT. The overall survival for patients who under-
went a 2nd HSCT was 61% (27/44) with a median overall
survival of 3.8 years (range: 0.2yrs to >10 yrs) and better
survival for patients with non-malignant (21/30) versus
malignant disease (6/14). There was no difference in survival
between patients with primary versus secondary graft fail-
ures. Infection was the primary cause of death (9/17). For 13
patients who failed to engraft after 2nd HSCT, 3 patients died
and 10 patients received a 3rd HSCT of whom 5 patients
survive. Thus 61% of pediatric patients can achieve graft
salvage from a second transplant, and half of the continuing
graft failures can be rescued by a third HSCT.284
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Several studies have demonstrated that a therapeutic
Cyclosporine (CsA) concentration within one week following
graft infusion correlates with a reduced risk of grade III-IV
acute graft versus host disease (aGVHD). Therefore, to begin
a quality improvement (QI) project we performed a retro-
spective chart analysis to determine when, using our stan-
dard approach to initial CsA dosing, our allogeneic bone
marrow transplant patients ﬁrst achieved therapeutic CsA
levels (Trough¼150-250ng/ml). Fifty three allogeneic trans-
plants were performed during the period assessed, of which
47 were eligible for evaluation. Patients were excluded from
analysis due to alternate GVH prophylaxis or major drug
interactions. In this historical cohort, CsA prophylaxis was
initiated as follows: loading with Cyclosporine, 2mg/kg/dose
IV Q 12 hrs for two days (day -2 and day-1) then decreasing
to 1.5mg/kg/dose IV Q 12 hrs. Using this approach, 34% of
patients had therapeutic levels within the ﬁrst 3 days
following transplant. Following this baseline analysis, we
initiated a QI intervention aimed at achieving a therapeutic
trough CsA level in at least 80% of patients by Day +3. To
accomplish this, the following new CsA regimen was insti-
tuted. Patients 5 years or older received Cyclosporine at
2.5mg/kg/dose IV Q 12 hrs beginning on day -3, and patients
less than 5 years of age received Cyclosporine at 2.5mg/kg/
dose IV Q 8 beginning on day -3. If the trough level was
subtherapeutic (below 100 NG/ML) on day 0, we gave an
extra 2mg/kg/loading dose IV, then increased the basal dose
by20%. If the level was between 100 and 149, we increased
the basal dose by 20% without an additional loading dose.
The impact of this intervention on the percentage of patientsachieving therapeutic CsA levels between Day 0 and Day + 3
was then assessed. To date, we have performed 28 trans-
plants under the new CsA regimen. Of these, 23 patients
were evaluable. Five patients were excluded per the previous
criteria. Using the new dosing guidelines, 87% of patients
achieved therapeutic CsA levels in the Day 0 to Day +3
window. This represent a statiscally signiﬁcant improvement
over our previous dosing regimen in which 34% of patients
achieved therapeutic CsA levels by Day +3 (P < .0003). No
patients had supratherapeutic CsA levels, deﬁned as greater
than 400 ng/ml within the ﬁrst 3 days post transplant. One
patient did exhibit nephrotoxicity, deﬁned as a persistent
doubling of the serum creatinine by Day +10. This patient
also had Adeno and BK viruria at Day 0 which confounds
assessment of causation. Overall, the revised dosing regimen
is both well tolerated and more effective in achieving the
targeted CsA level in 80% of cases (95% conﬁdence interval,
68-95%). Following completion of this project, we plan
further analyses to determine whether this practice change
has impacted rates of aGVHD in our patient population.285
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In adults, hepatic complications following allogeneic
hematopoietic stem cell transplantation (AlloHSCT) are
associated with signiﬁcant morbidity and transplant related
mortality (TRM). However, there is a paucity of parallel data
on the incidence of, and risk factors for, liver injury (LI) and
the impact of LI on TRM in pediatric AlloHSCT recipients.
Methods: We compared total bilirubin, direct bilirubin and
alanine aminotransferase values pre-AlloHSCT and at
1month, day +100 and 12 months post-AlloHSCT in 248
patients following myeloablative conditioning (MAC) or
reduced toxicity/reduced intensity conditioning (RTC/RIC).
Liver injury was deﬁned as  Grade 2 toxicities according to
the NCI CTCAE 3.0/4.0 or total bilirubin 1.95mg/dL (1.5 times
above upper limit of normal). Univariate and multivariate
logistic regression models were used to identify risk factors
for the incidences of LI and TRM.
Results: 248 eligible patients received MAC (n¼109) or RTC/
RIC AlloHSCT (n¼139). The incidence of LI at 1 month post-
AlloSCT was signiﬁcantly higher in MAC vs. RTC/RIC
AlloHSCT based on total bilirubin levels (21.9% vs. 7.8%; P ¼
.0067). There was no signiﬁcant difference in LI pre-
AlloHSCT, LI at day +100 and 12 months post-AlloHSCT
between the two groups. The TRM among patients with LI at
1 month post-AlloHSCT was as 64.2% (CI95 49%, 79.4%)
